Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

Published on by Forensic Scientist

Dr. Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

University of Wisconsin-Madison | United States

Dr. Jacques Galipeau is a leading translational immunologist recognized for seminal contributions to mesenchymal stromal cell (MSC) biology, immune modulation, and engineered cytokine therapeutics. His research has reshaped global understanding of MSC immunogenicity, functional potency, and clinical limitations, directly influencing regulatory science and advanced cell therapy development. He pioneered the discovery and translation of fusokines, a novel class of synthetic cytokines with applications in autoimmunity, cancer immunotherapy, transplantation tolerance, and regenerative medicine. His work bridges mechanistic immunology and first-in-human translation, with sustained impact across academia and clinical development. According to Google Scholar, Dr. Jacques Galipeau has authored 478 peer-reviewed publications, received 23244 citations, and holds an h-index exceeding 71, reflecting sustained global influence.

                        Citation Metrics (Google Scholar)

30000

25000

20000

15000

10000

5000

0

 

Citations
23444
Documents
478
h-index
71

Citations

Documents

h-index

View Google Scholar Profile

Featured Publications


Mesenchymal stromal cells: clinical challenges and therapeutic opportunities

– J. Galipeau, L. Sensébé · Cell Stem Cell, 2018 · Cited by 1868


Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages

– J.S. Wang, D. Shum-Tim, J. Galipeau et al. · J Thorac Cardiovasc Surg, 2000 · Cited by 976


Mesenchymal stem versus stromal cells: ISCT® position statement on nomenclature

– S. Viswanathan, Y. Shi, J. Galipeau et al. · Cytotherapy, 2019 · Cited by 866

Human MSC suppression correlates with cytokine-induced IDO and M2 macrophage differentiation

– M. François, R. Romieu-Mourez, M. Li, J. Galipeau · Molecular Therapy, 2012 · Cited by 862

Allogeneic marrow stromal cells are immune-rejected by MHC-mismatched recipients

– N. Eliopoulos, J. Stagg, L. Lejeune et al. · Blood, 2005 · Cited by 700

Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Guilan University of Medical Sciences | Iran

Dr. Majid Taati Moghadam is a dedicated Medical Microbiologist and Antimicrobial Resistance Researcher based in Rasht, Iran. He specializes in microbial pathogenesis, antibiotic resistance mechanisms, bacteriophage therapy, and the connection between microbiota and neurodegenerative disorders. His multidisciplinary expertise extends across clinical microbiology, infectious disease prevention, and translational therapeutics, making him a leading figure in Iran’s microbiological research community.

Professional Profile

Scopus

Google Scholar

ORCID

Education

Dr. Majid Taati holds a Ph.D. in Medical Bacteriology from Iran University of Medical Sciences (2017–2022), where his research investigated the relationship between oral microbiome shifts and Alzheimer’s disease. He earned his Master’s degree in Medical Microbiology from Kerman University of Medical Sciences (2012–2015), focusing on carbapenem resistance genes in Klebsiella pneumoniae. His academic journey began with a Bachelor’s degree in Microbiology from Islamic Azad University, Lahijan Branch (2007–2012). Throughout his studies, he demonstrated a keen interest in antibiotic resistance, clinical diagnostics, and the molecular biology of pathogens.

Experience

Dr. Majid Taati has played key roles in over a dozen microbiological research projects across Iran. As both a principal investigator and main collaborator, he has contributed to studies on extended-spectrum beta-lactamase (ESBL) genes, resistance enzymes in E. coli, and the antimicrobial effects of plant extracts like Ephedra pachyclada. He has worked extensively on projects involving nosocomial infections, multidrug-resistant bacteria, and genetic analysis methods such as MLVA and HRM techniques. He also authored the textbook Essential Medical Microbiology in Persian, and presented his findings at several major Iranian congresses, including the International Microbiology Congress. His laboratory and academic experience bridges both applied research and educational leadership.

Research Interests

Dr. Majid Taati research focuses on antimicrobial resistance mechanisms, phage and endolysin therapy, bacterial biofilm inhibition, and engineered phage enzymes for resistant infections. He is also deeply involved in exploring the role of microbiota in neurological and neuropsychiatric disorders, especially Alzheimer’s disease. His studies aim to bridge clinical microbiology with therapeutic innovation addressing global health threats posed by superbugs like carbapenem- and colistin-resistant Gram-negative bacteria. His recent projects extend to wound healing biomaterials, phage protein therapies, and microbiome-based diagnostics, reflecting his broad and multidisciplinary scientific interests.

Awards

Recognized for his extensive research contributions, Dr. Majid Taati is a deserving nominee for the “Best Researcher Award” in medical microbiology and antimicrobial resistance. His scholarly excellence, particularly in phage therapy and resistance gene profiling, aligns well with the objectives of scientific bodies that honor groundbreaking research. With dozens of publications in top-tier journals and continuous involvement in nationally significant projects, he exemplifies leadership in translational microbiology and global infectious disease research.

Publications

  • Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
    Year: 2020
    Citations: 316

  • Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
    Year: 2020
    Citations: 311

  • How phages overcome the challenges of drug resistant bacteria in clinical infections
    Year: 2020
    Citations: 173

  • Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials
    Year: 2020
    Citations: 125

  • COVID-19 (Coronavirus disease 2019): a new coronavirus disease
    Year: 2020
    Citations: 108

  • Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples
    Year: 2019
    Citations: 108

  • Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria
    Year: 2021
    Citations: 58

Conclusion

Dr. Majid Taati Moghaddam Ziabari has built an impressive career defined by scientific innovation, deep academic rigor, and a commitment to combating infectious diseases. His pioneering work in bacteriophage therapy and antimicrobial resistance not only advances microbiological science but also addresses some of the most urgent global health challenges. With his rich publication record, research leadership, and academic influence, he is a prime candidate for international recognition, especially the Best Researcher Award. His career serves as a model of excellence in translational research and academic impact.

Lina Fan | Microbiology | Best Researcher Award

Published on by Forensic Scientist

Dr. Lina Fan | Microbiology | Best Researcher Award

Distinguished researcher | The Second Affiliated Hospital of Zhejiang University School of Medicine | China

Lina Fan is a distinguished researcher and physician, specializing in gut microbiota, immune microenvironment, and colorectal tumorigenesis. She obtained her Ph.D. from Zhejiang University and currently works as a gastroenterologist at the Second Affiliated Hospital of Zhejiang University School of Medicine. Her work focuses on the intricate relationship between gut microbiota and cancer, contributing significantly to the field with several impactful publications.

Profile

Scopus

Strengths for the Awards

  • Strong Academic Background:
    • Lina holds a Ph.D. from Zhejiang University, a prestigious institution, and works as a distinguished researcher and physician.
  • Research Focus:
    • Her research is centered on the highly impactful areas of gut microbiota, immune microenvironment, and colorectal cancer, all of which have significant implications for medical science.
  • High-Quality Contributions:
    • She has contributed significantly to the understanding of gut microbiota’s relationship with colorectal cancer and immune microenvironments, evidenced by the completion of substantial research on Bifidobacterium adolescentis and other microbiota in colorectal cancer.
  • Publications and Editorial Appointments:
    • Although there is no explicit mention of indexed journal publications, Lina holds editorial positions in well-regarded journals such as Cancer Immunology Research, Gut Microbes, and Cancer Communications, showcasing recognition from the research community.

Education 🎓

Lina Fan earned her Ph.D. from Zhejiang University, where she honed her expertise in gastrointestinal research. As a researcher and physician, she has contributed to advancements in understanding the immune microenvironment and gut microbiota’s role in colorectal cancer, laying the foundation for her future work.

Experience 🏥

Lina has served as a gastroenterologist and researcher at the Second Affiliated Hospital of Zhejiang University School of Medicine. She has been actively involved in studies examining the gut microbiota, immune system, and their relationship to digestive cancers, particularly colorectal cancer, producing multiple high-impact research articles in the process.

Research Interests On Microbiology🔬

Her research interests center on gut microbiota, the immune microenvironment, and their roles in colorectal tumorigenesis. Specifically, Lina has worked on understanding how specific microbes, like Bifidobacterium adolescentis, influence cancer development. Her ongoing projects explore the effects of gut microbiota on metabolic syndrome and the immune response in cancer.

Awards 🏆

Lina has been nominated for prestigious awards, including the Young Scientist Award and the Best Researcher Award, recognizing her groundbreaking work in cancer immunology and microbiome research. Her research has been recognized both nationally and internationally for its innovation and contributions to the scientific community.

Publications 📰

  • Lactobacillus intestinalis facilitates tumor-derived CCL5 to recruit dendritic cell and suppress colorectal tumorigenesis
    • Authors: Sun, Y., Wang, Q., Jiang, Y., Chen, S., Fan, L.
    • Year: 2025
    • Citations: 0
  • Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer
    • Authors: Jia, D., Wang, Q., Qi, Y., Chen, S., Wang, L.
    • Year: 2024
    • Citations: 47
  • Correction: Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis
    • Authors: Lin, Y., Fan, L., Qi, Y., Chen, S., Wang, L.
    • Year: 2023
    • Citations: 0
  • Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis
    • Authors: Lin, Y., Fan, L., Qi, Y., Chen, S., Wang, L.
    • Year: 2023
    • Citations: 19
  • Bifidobacterium adolescentis orchestrates CD143+ cancer-associated fibroblasts to suppress colorectal tumorigenesis by Wnt signaling-regulated GAS1
    • Authors: Chen, S., Fan, L., Lin, Y., Si, J., Wang, L.
    • Year: 2023
    • Citations: 14
  • Lactobacillus johnsonii alleviates colitis by TLR1/2-STAT3 mediated CD206+ macrophagesIL-10 activation
    • Authors: Jia, D.-J.-C., Wang, Q.-W., Hu, Y.-Y., Chen, S.-J., Wang, L.-J.
    • Year: 2022
    • Citations: 70
  • Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-induced acute colitis by NLRP3 activation
    • Authors: Qu, S., Fan, L., Qi, Y., Liu, W., Si, J.
    • Year: 2021
    • Citations: 153
  • Akkermansia muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs
    • Authors: Fan, L., Xu, C., Ge, Q., Chen, S., Wang, L.
    • Year: 2021
    • Citations: 94
  • Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization
    • Authors: Xu, C., Fan, L., Lin, Y., Si, J., Chen, S.
    • Year: 2021
    • Citations: 146
  • Bifidobacterium adolescentis ameliorates chronic colitis by regulating Treg/Th2 response and gut microbiota remodeling
    • Authors: Fan, L., Qi, Y., Qu, S., Si, J., Chen, S.
    • Year: 2021
    • Citations: 141

Conclusion

Dr. Lina Fan’s research has made significant strides in exploring the complex relationship between gut microbiota and colorectal cancer. Her work continues to shape the field, with groundbreaking findings that may lead to novel therapeutic strategies. With her commitment to advancing medical knowledge, she is undoubtedly a key figure in the scientific community.

Fizza Khalid | microbiology | Best Researchrer Award

Published on by Forensic Scientist

Dr. Fizza Khalid | microbiology | Best Researcher Award

clinical scientist at Dr Sulaiman Al-Habib Medical Diagnostic Laboratory , Saudi Arabia

Dr. Fizza Khalid is a dedicated microbiologist with extensive expertise in laboratory research, antimicrobial resistance, and clinical microbiology. With a Ph.D. in Medical Microbiology from the University of Health Sciences, Lahore, she has a proven track record of characterizing drug-resistant bacteria and developing innovative treatment strategies. Currently, she is the Deputy Head of the Clinical Research Committee and a Specialized Lab Supervisor at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. Dr. Khalid is passionate about advancing microbiological research to improve healthcare outcomes and has published several impactful studies in leading international journals.

Profile

ORCID

Educational

  • Ph.D. in Medical Microbiology (2016–2023) – University of Health Sciences, Lahore
    Thesis: Characterization of Locally Isolated Acinetobacter baumannii Strains for Drug Resistance and Biofilm Formation
  • M.Phil. in Medical Microbiology (2012–2014) – University of Health Sciences, Lahore
    Thesis: In-vitro Efficacy of Polymyxin B with Rifampin, Colistin, and Doxycycline Against Extensively Drug Resistant Acinetobacter baumannii
  • M.Sc. in Medical Technology (2008–2010) – University of Health Sciences, Lahore
    Thesis: Frequency of Extended Spectrum Beta Lactamase Enzymes in the Clinical Isolates of Salmonella Typhi
  • B.Sc. in Medical Laboratory Technology (2005–2007) – University of Health Sciences, Lahore

Professional Experience

Dr. Fizza Khalid currently serves as the Deputy Head of the Clinical Research Committee and Specialized Lab Supervisor in Microbiology at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. In her role, she leads clinical microbiology operations, collaborates with healthcare professionals, ensures regulatory compliance, and conducts research presented at international conferences. Previously, she was a Senior Lab Technologist at the same group, where she developed standard operating protocols, performed clinical microbiology analysis, and ensured testing quality and safety compliance. Throughout her career, Dr. Khalid has mentored junior researchers, promoted clinical research, and conducted workshops to enhance scientific study design and writing skills.

Research Interests

Dr. Khalid’s research focuses on antimicrobial resistance, particularly in Acinetobacter baum                                                                                             annii and Salmonella Typhi, biofilm formation, and the effectiveness of novel treatment strategies against drug-resistant bacterial strains. She has a keen interest in developing antimicrobial agents, studying bacterial genotyping, and investigating synergistic antibiotic combinations to combat multidrug-resistant pathogens. Her research contributes to understanding the molecular mechanisms of resistance and finding practical applications for improving patient care in clinical settings.

Author Metrics

  • Published Papers: 14 peer-reviewed articles, including journals such as Clinica Chimica Acta, JPMA, Scientific Reports, and Annals of Clinical Microbiology and Antimicrobials.
  • Citations: Her work has been widely cited in the fields of antimicrobial resistance and biofilm research.
  • H-index: Reflects her contributions to microbiology, particularly in research related to Acinetobacter baumannii and Salmonella Typhi.

Publication

Conclusion

Fizza Khalid presents an excellent case for the Best Researcher Award in medical microbiology, with notable strengths in antibiotic resistance research, an impressive publication record, and practical lab expertise. Her leadership role in facilitating junior researchers and fostering a culture of research also speaks to her broader contribution to the scientific community. With a few targeted improvements, such as securing international collaborations and focusing her research scope, she can further strengthen her candidacy for the award.

In conclusion, Khalid’s achievements in medical microbiology, particularly her work on MDR pathogens, make her a strong contender for the Best Researcher Award, demonstrating both scientific excellence and leadership in her field.